R
Replimune Group, Inc. (REPL)
NMS – Real Time Price. Currency in USD
4.09
+0.35 (9.36%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
4.09
+0.35 (9.36%)
At close: May 12, 2026, 4:00 PM EDT
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Name | Position |
|---|---|
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Sushil Patel Ph.D. | CEO & Director |
| Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Mr. Camilo Garcia M.A., M.B.A. | Chief Human Resource Officer |
| Mr. Christopher Sarchi | Chief Commercial Officer |
| Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman |
| Mr. Shawn Glidden J.D. | Senior VP & General Counsel |
| Ms. Emily Luisa Hill | Chief Financial Officer |
| Ms. Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management |
| Date | Type | Document |
|---|---|---|
| 2026-04-13 | 8-K | tm2611633d1_8k.htm |
| 2026-02-03 | 10-Q | repl-20251231.htm |
| 2026-01-12 | 8-K | tm262890d1_8k.htm |
| 2025-11-06 | S-3/A | tm2530049-1_s3a.htm |
| 2025-10-20 | 8-K | tm2529069d1_8k.htm |
| 2025-09-18 | 8-K | tm2526397d1_8k.htm |
| 2025-09-04 | 8-K | tm2525185d1_8k.htm |
| 2025-08-07 | 8-K | tm2522849d1_8k.htm |
| 2025-08-07 | 10-Q | repl-20250630.htm |
| 2025-07-25 | DEFA14A | tm2521674d3_defa14a.htm |